PAR-25-444 CCSG P30 eligibility Guide
Updated 14 official sources
Quick Answer: PAR-25-444 is NCI's current P30 Cancer Center Support Grant (CCSG) notice for NCI-Designated Cancer Centers.
Full answer and how we checked it
According to the notice, a new center needs a cancer-focused NIH funding base of $6 million (Basic) or $10 million (Clinical) a year, can request up to $1.2 million or $1.4 million in direct costs, and can next apply January 25, 2027. NCI lists 74 designated centers.
Who this is for: This guide is for cancer center directors, associate directors for administration, research deans, shared-resource leaders, clinical trials office leaders, and sponsored-research offices deciding whether a new or renewal P30 CCSG application is ready for a 2027 or 2028 due date.
Data note: This guide uses the PAR-25-444 full announcement on Simpler.Grants.gov, NCI's cancer centers program pages and Office of Cancer Centers resources, NIH Guide notices on Common Forms, indirect costs, and the Unified Funding Strategy, and award data from the NIH RePORTER API and the USAspending.gov API. Grantsights rechecked the due dates, caps, eligibility rules, and review criteria against the announcement on October 18, 2026.
Source review by Grantsights, October 18, 2026: We rechecked PAR-25-444, NCI's cancer centers program page and center list, Office of Cancer Centers CCSG resources and benchmark data, NIH's simplified review page, NOT-OD-26-018, NOT-OD-26-099, NOT-OD-25-068, and FY2026 NCI P30 award records. Where official sources stop: The NOFO doesn't publish a renewal budget formula, and NCI doesn't post per-center paylines for the CCSG.
In this guide
- October 2026 Source Check
- 7 PAR-25-444 Eligibility Stop Checks
- 5 Source Facts Applicants Should Know
- What 74 CCSG Awards Look Like in FY2026
- How Reviewers Score a P30 in 2026
- NIH-Wide Changes in 2025 and 2026 That Touch a CCSG
- What NCI Doesn't Tell You
- 6 Evidence Assets That Make This P30 Stronger
- 5 Route Choices Before Drafting
- 6 Bad-Fit Signals
- 21-Day CCSG Readiness Plan
- 5 Evidence Tables to Build Before Writing
- 7 CCSG Checks Before You Commit a Cycle
- Sources
PAR-25-444 isn't a normal research-project grant. According to the PAR-25-444 full announcement (opens in a new tab), the CCSG pays for scientific leadership, Shared Resources for funded center investigators, certain administrative costs, planning and evaluation, and developmental funds for new recruitments and feasibility studies. The research itself has to be paid for by the center members' own peer-reviewed grants.
So the decision isn't "do we do cancer research?" It's whether the institution has a countable cancer research base, a center director with real authority, Shared Resources that members actually use, and the data tables to prove it to the Cancer Centers study section.
Use this guide with the live NCI Cancer Center Support Grants P30 program record and the Grantsights grant database. For background on NIH mechanics, the NIH grants complete guide and what is a NOFO cover the basics this guide skips.
October 2026 Source Check
Grantsights checked the PAR-25-444 due-date table again on October 18, 2026. The notice opened December 1, 2025, and the September 25, 2026 date has passed. The next three dates are January 25, 2027, May 25, 2027, and September 25, 2027, followed by three more in 2028 through September 25, 2028. Applications are due by 5 p.m. local time of the applicant organization, and the notice expires September 26, 2028.
| Due date | Scientific merit review | Advisory council | Earliest start |
|---|---|---|---|
| January 25, 2027 | July 2027 | October 2027 | December 2027 |
| May 25, 2027 | November 2027 | January 2028 | April 2028 |
| September 25, 2027 | March 2028 | May 2028 | July 2028 |
| January 25, 2028 | July 2028 | October 2028 | December 2028 |
That schedule means a CCSG submitted in January 2027 won't start until December 2027 at the earliest, about 11 months later. Renewal centers should line up the due date with the end of the current project period so there's no gap.
According to the notice, the budget rule is the same as when it opened: new Type 1 applications shouldn't exceed $1.2 million a year for Basic Cancer Centers, $1.4 million for Clinical Cancer Centers, or $1.5 million for Comprehensive Cancer Centers, all in direct costs. Renewal budgets aren't capped but have to reflect actual needs. The base project period is 5 years, and NCI says some centers may qualify for two more years (seven in total) based on merit at review, sustained progress, stability, NCI staff review, and National Cancer Advisory Board approval.
Get research funding calls by email
About once a week, we email open research funding calls with a real deadline, from federal agencies such as NIH and NSF, picked for research institutions. One click to unsubscribe.
No spam. Unsubscribe anytime.
7 PAR-25-444 Eligibility Stop Checks
PAR-25-444 sets 7 hard lines a new or renewal applicant has to clear before anything else matters. The first is money: according to the announcement, a new applicant needs a cancer-focused funding base of $10,000,000 (Clinical) or $6,000,000 (Basic) in annual NIH direct costs, measured by NIH's Research, Condition, and Disease Categorization (RCDC) system. A renewal needs at least $10,000,000 in annual direct costs of peer-reviewed, cancer-related funding.
| Stop check | PAR-25-444 rule | Red flag |
|---|---|---|
| Funding base | $6M (Basic) or $10M (Clinical) new; $10M renewal, RCDC cancer-coded | The count depends on grants that aren't RCDC-coded as cancer |
| Center type | Basic, Clinical, or Comprehensive; new applicants can't request Comprehensive status | Leadership expects Comprehensive on the first try |
| One application | Only one per institution (unique UEI or NIH IPF number) | Two departments plan separate centers |
| Research Programs | At least 7 R01-equivalent cancer projects from 5+ independent PIs per Program | A Program is built around 2 or 3 strong labs |
| Shared Resources | At least 1 Shared Resource component, with users and member share | Cores are wish-list items with no usage data |
| Consortium | Only renewals may propose one, and it must already be working | A new application adds a partner hospital |
| Foreign entities | Not eligible; foreign components aren't allowed | Key work sits at a non-U.S. site |
The NOFO defines R01-equivalence as a project funded for at least 3 years with at least $125,000 in direct costs a year, and grants on no-cost extension don't count. A common mistake is counting a member's no-cost-extension R01 toward a Program's 7-project floor. The Program falls below the line and the whole component weakens.
Another red flag is treating the CCSG as recognition. It isn't. It's a peer-reviewed operating model for a cancer center, and the designation follows the award.
5 Source Facts Applicants Should Know
Five facts from the notice belong at the top of any internal go/no-go memo. According to the PAR-25-444 full announcement (opens in a new tab), PAR-25-444 reissues PAR-21-321, uses activity code P30, is clinical trial optional, carries assistance listing 93.397, and sets a 5-year base project period.
According to the Simpler.Grants.gov PAR-25-444 listing (opens in a new tab), the opportunity's last application date is September 25, 2028. According to USAspending award data, Grantsights analysis of FY2024 records on USAspending.gov (opens in a new tab) found that assistance listing 93.397 carried about $589.4 million in obligations across 120 recipients. That listing is broader than the CCSG alone (NIH RePORTER shows 74 CCSG awards in FY2026), so use it for context, not for benchmarking a center budget.
| CCSG notice item | What PAR-25-444 says |
|---|---|
| Notice number | PAR-25-444 (reissue of PAR-21-321) |
| Mechanism | P30 Center Core Grant |
| Clinical trial status | Optional |
| New direct-cost caps | $1.2M Basic, $1.4M Clinical, $1.5M Comprehensive per year |
| Renewal budget | Not capped; must reflect actual needs |
| Next date | January 25, 2027 |
| Expiration | September 26, 2028 |
Every CCSG request is far above $500,000 in direct costs, so the NOFO's rule applies: contact an NCI Scientific/Research Contact at least 6 weeks before submitting. For the Office of Cancer Centers' own guidance, start with the CCSG resources page (opens in a new tab).
What 74 CCSG Awards Look Like in FY2026
According to the NCI Cancer Centers Program's center overview (opens in a new tab), there are 74 NCI-Designated Cancer Centers in 37 states and the District of Columbia: 58 Comprehensive, 8 Clinical, and 8 Basic Laboratory centers. The award data lines up with that count.
Grantsights analysis of NIH RePORTER data found 74 distinct NCI P30 CA core projects with FY2026 funding, totaling about $333.3 million. Method: on October 18, 2026, Grantsights queried the NIH RePORTER API (opens in a new tab) for fiscal year 2026, activity code P30, agency NCI, kept the 75 parent award records (dropping 1,358 sub-project component records), and summed award amounts by core project number.
| FY2026 NCI P30 measure | Total cost (direct + F&A) | Direct cost |
|---|---|---|
| Centers with FY2026 funding | 74 | 74 |
| Median per center | $3.99M | $2.37M |
| Middle half of centers | $2.68M to $5.71M | $1.60M to $3.66M |
| Largest award | $13.13M (Memorial Sloan Kettering) | $7.46M |
| Centers at $10M or more | 4 | n/a |
| Centers at $1.5M direct or less | n/a | 13 |
The four largest FY2026 awards went to Memorial Sloan Kettering ($13.13 million), Dana-Farber ($12.78 million), MD Anderson ($11.51 million), and Fred Hutchinson ($11.39 million), together about 15% of the total. At the other end, the smallest full awards were about $1.9 million in total costs. Budget periods vary by center, so treat these as FY2026 award amounts, not annualized rates. One record (Virginia Commonwealth University) showed a total below its direct cost and was left out of the low-end comparison.
The FY2026 file also shows how few centers are new: 1 Type 1 award, 12 renewals (Type 2), and 55 non-competing continuations. The finding that changes planning is at the small end. For example, Purdue received a renewal (2P30CA023168-45) in FY2026 at $1,200,012 in direct costs, essentially the same as the $1.2 million Basic cap for a new center. Renewal budgets aren't capped, but that doesn't mean they grow on their own.
Two real awards show how new centers sit against the caps:
- One center in Urbana, the Cancer Center at Illinois (opens in a new tab) (a Basic Laboratory Cancer Center), received its first CCSG in FY2026 at $1,199,997 in direct costs and $1,903,195 in total costs, $3 under the Basic cap.
- One center in Rochester, New York, the Wilmot Cancer Institute (opens in a new tab) (a Clinical Cancer Center), received its first CCSG in FY2025 at $1,347,885 in direct costs, under the $1.4 million Clinical cap, and the same amount again in FY2026.
Both were funded on resubmission (the "-01A1" suffix), and Fox Chase's FY2025 renewal was an A1 too. Plan for the chance that the first submission won't be funded. Using the due-date table above, an A0 submitted January 25, 2027 and reviewed in July 2027 can't come back as an A1 before September 25, 2027, which pushes the earliest start from December 2027 to July 2028. The NIH resubmission guide covers the A1 rules.
How Reviewers Score a P30 in 2026
NIH's simplified review framework, which started with January 25, 2025 due dates, applies to most research project grants. According to NIH's simplified review page (opens in a new tab), it covers "the majority of competing research project grant (RPG) applications." A P30 center grant isn't an RPG, and PAR-25-444's Section V keeps the older structure.
Grantsights checked Section V of the notice. Reviewers give separate scores for 5 criteria (Significance, Investigators, Innovation, Approach, Environment), then weigh additional review criteria built on the Six Essential Characteristics: Physical Space, Organizational Capabilities, Transdisciplinary Collaboration and Coordination, Cancer Focus, Institutional Commitment, and Center Director. Consortium plans and requests for Comprehensive status are rated satisfactory or unsatisfactory and don't feed the impact score.
The test reviewers are told to apply is value added. The NOFO says that if a center would have reported similar achievements without the CCSG, the value added would be minimal, and reviewers are told to stress that in the overall impact score. Applications may also go through a selection step where only those in roughly the top half are discussed and scored.
For centers used to R01 summary statements, the NIH summary statement guide and the NIH grant score explainer explain impact scores and percentiles. CCSG scores are read alongside NCI priorities rather than a fixed payline, a point the NCI payline guide covers for NCI as a whole.
NIH-Wide Changes in 2025 and 2026 That Touch a CCSG
Three NIH-wide changes from the past 2 years affect how a CCSG is prepared and funded.
Unified Funding Strategy. According to NIH notice NOT-OD-26-099 (opens in a new tab), the NIH Director announced the Unified Funding Strategy in August 2025. Funding decisions weigh peer review scores together with Institute priorities, scientific opportunity, program balance, geographic balance, and workforce needs. For a CCSG, that means a good score is necessary but doesn't guarantee an award, and the geographic and catchment story carries weight at the funding stage too.
Indirect costs. NIH's February 2025 Supplemental Guidance, NOT-OD-25-068 (opens in a new tab), set a standard 15% indirect rate for all NIH grants. A federal district court permanently blocked it in 2025, and the U.S. Court of Appeals for the First Circuit ruled against the cap on January 5, 2026, with the mandate issued February 27, 2026, per the Georgetown Law litigation tracker (opens in a new tab). Awards still use negotiated F&A rates. According to NIH RePORTER data for FY2026, F&A made up about 38% of NCI P30 dollars ($125.5 million of $334.7 million in direct plus F&A costs), and the median center's F&A was about $1.45 million, so the rate matters. The indirect cost rate negotiation guide covers how those rates are set.
Common Forms. According to NIH notice NOT-OD-26-018 (opens in a new tab), the Common Forms for Biographical Sketch and Current and Pending (Other) Support, plus a new NIH Biographical Sketch Supplement, are required for due dates on or after January 25, 2026. A CCSG lists dozens of senior and key people across Programs and Shared Resources, so every one of them needs the new forms in SciENcv. Since January 25, 2026, anyone currently in a malign foreign talent recruitment program can't serve as senior/key personnel. The NIH biosketch guide walks through the new format.
What NCI Doesn't Tell You
Four readiness problems sink CCSG applications more often than weak science, and none of them shows up in the 5-year, $1.2 million headline. First, the research base has to be countable and cancer-relevant by RCDC, not by the center's own judgment. If grants can't be mapped to Programs and members, the rest of the application fails because Data Table 2A won't hold up.
Second, Shared Resources have to show real use. The NOFO asks for the total number of users and the number and percent who are center members. A core that exists on paper but lacks member demand, quality controls, and a chargeback model will weaken the center story. The CCSG pays for stable operating costs and small equipment replacement under $25,000, not for the variable costs of individual projects.
Third, consortium rules are strict. Only Type 2 renewals may propose a consortium, and a clinical partner must hold at least $2.5 million in RCDC cancer-coded direct costs from at least 10 PIs (a non-clinical partner, $1.0 million from 5 PIs). The partner's protocols must run through the center's PRMS, DSMP, and CPDM, and the partner has to give the center director some influence over its clinical cancer care.
Fourth, the director's authority has to be documented. Reviewers ask whether the director controls member appointments, faculty recruitment, clinical research facilities, and institutional and philanthropic resources, and whether there's a succession plan. A center that answers to a single department chair underestimates how hard reviewers will press on this.
6 Evidence Assets That Make This P30 Stronger
PAR-25-444 asks for 5 numbered data tables (DT1 through DT5), and each one maps to an evidence asset the center should build first. Asset 1 is the research-base table: every active cancer-related project by PI, mechanism, dates, direct costs, and Program, in Data Table 2A format.
Asset 2 is the Shared Resource utilization record: users, member share, services, quality controls, pricing, subsidies, and publications. Asset 3 is a governance map showing senior leaders, Program and Shared Resource leaders, the External Advisory Committee, and decision rights.
Asset 4 is a strategic plan with priorities, recruitments, investments, and measurable outcomes. Asset 5, for Clinical and Comprehensive applicants, is the clinical research oversight package: PRMS, DSMP, CPDM, and Data Table 4 trial lists. Renewals must generate DT4 interventional treatment trials from NCI's Clinical Trials Reporting Program; new applicants don't have to use CTRP.
Asset 6 is a population-based catchment definition and Community Outreach and Engagement plan. The NOFO says the catchment area must include the area where most patients come from and the local area around the center, using census tracts, ZIP codes, or county or state lines. For benchmarks, the Office of Cancer Centers benchmark data (opens in a new tab) compiles what designated centers report in the same four data tables.
5 Route Choices Before Drafting
Five routes are worth comparing before a center commits to a CCSG with at least 7 required components (10 for Clinical and Comprehensive centers).
| Route | Better first move when... | Why |
|---|---|---|
| PAR-25-444 P30 | The RCDC base clears $6M or $10M and Programs meet the 7-project floor | Route fits |
| Build the research base first | The RCDC count is short of the threshold | The NOFO's eligibility floor isn't met yet |
| P01 or Parent P50 | A defined science area needs program-level support | Full CCSG scope may be too broad |
| R01 and R35 recruitment strategy | Programs fall short of 5 independent PIs | More investigator funding is the gap |
| Shared instrumentation (S10) | One core's equipment is the main need | P30 is too much for one instrument |
The honest answer is that many institutions should spend a year or more adding R01-equivalent cancer awards and Shared Resource usage data before drafting. If one core instrument is the real need, the NIH S10 instrumentation guide is a better first read.
6 Bad-Fit Signals
Six signals mean a center should hold off on the next due date. First, the RCDC funding base is below $6 million (Basic) or $10 million (Clinical). Second, a Program can't show 7 R01-equivalent cancer projects from 5 independent PIs.
Third, Shared Resources have weak usage or quality evidence. Fourth, clinical-trial oversight is split across units with no center authority. Fifth, a new application relies on consortium partners, which the notice doesn't allow. Sixth, the budget is a broad institutional wish list instead of a center operating plan inside the $1.2 million or $1.4 million cap.
Take a hypothetical case: an academic medical center in the Midwest with strong cancer investigators but no unified PRMS or Shared Resource data should fix its operating model before treating PAR-25-444 as a near-term target.
21-Day CCSG Readiness Plan
A 21-day internal review can answer the go/no-go question before anyone starts writing. Days 1 through 3 should confirm the due date, center type, budget cap, and whether NCI's Office of Cancer Centers agrees with the RCDC funding-base count.
Days 4 through 7 should audit the funded research base by member and Program against the 7-project, 5-PI floor. Days 8 through 12 should audit Shared Resources: users, member share, pricing, quality, and cost recovery.
Days 13 through 16 should review governance, director authority, clinical trial oversight, community engagement, and training coordination. Days 17 through 21 should produce the no-go memo. If the center can't show operating authority and a countable funded research base, don't draft yet.
5 Evidence Tables to Build Before Writing
Build 5 evidence tables before assigning component writers, because the page limits leave no room to explain gaps. The Overall component gets 30 pages; Administration, each Research Program, Shared Resource Management, Leadership Planning and Evaluation, Community Outreach and Engagement, Developmental Funds, CPDM, and PRMS get 12 each; each Shared Resource and the training coordination component get 6.
Table 1 is the funded research base by member, Program, grant number, award dates, direct costs, and RCDC cancer coding. Table 2 is the Shared Resource table by core, service, users, member share, publications, and cost recovery. Table 3 is clinical research oversight: PRMS, DSMP, CPDM, accrual, and protocol activation timelines.
Table 4 is the catchment table, covering population, cancer burden, community partners, and research use. Table 5 is the institutional investment table: commitments, recruitments, space, and the formula-based return of clinical revenue or F&A that the NOFO names as evidence of stable support. Renewals also file DT5, which compares the last full non-competing year's budget with the request.
If those 5 tables can't be produced, don't treat PAR-25-444 as a near-term writing project. Use the gap list to build the center first.
7 CCSG Checks Before You Commit a Cycle
Grantsights checked each of these 7 items against the PAR-25-444 announcement, NCI's center list, and FY2026 RePORTER records on October 18, 2026.
| CCSG check | What PAR-25-444 or NCI data says |
|---|---|
| RCDC funding base | New: $6M Basic or $10M Clinical; renewal: $10M; ask the Office of Cancer Centers to confirm the count |
| Center type and cap | Basic $1.2M, Clinical $1.4M direct per year for new; Comprehensive status only on renewal |
| Program size | 7+ R01-equivalent projects ($125,000+ direct, 3+ years) from 5+ PIs per Program |
| Required components | Overall, Administration, training coordination, SRM, LPE, 1+ Shared Resource, 1+ Program; COE, CPDM, PRMS for Clinical and Comprehensive |
| NCI contact | Required at least 6 weeks before submission for any request of $500,000+ direct |
| Review | 5 scored criteria plus Six Essential Characteristics; not the 2025 simplified framework |
| Funding odds | FY2026 had 1 new award among 74; recent new centers were funded on resubmission |
Cancer centers that also hold NCI network awards should compare this guide with the NCI NCTN and EET Biobanks record. That forecast is a limited competition for existing NCTN or EET biobank recipients, not a general P30 center-support route. NIEHS runs a separate center core program, covered in the Environmental Health Sciences Core Centers P30 guide, and NCI's education awards are in the NCI R25 guide.
Final checklist
- Confirm the RCDC funding base with NCI's Office of Cancer Centers before committing a due date.
- Check every Program against the 7-project, 5-PI floor and drop no-cost-extension grants from the count.
- Hold the Type 1 budget inside the $1.2 million or $1.4 million direct-cost cap.
- Get Common Forms biosketches and Current and Pending (Other) Support in SciENcv for every senior/key person.
Sources
- PAR-25-444 full announcement (opens in a new tab)
- Simpler.Grants.gov PAR-25-444 listing (opens in a new tab)
- NCI cancer centers program (opens in a new tab)
- NCI list of designated cancer centers (opens in a new tab)
- NCI Office of Cancer Centers CCSG resources (opens in a new tab)
- NCI Office of Cancer Centers benchmark data (opens in a new tab)
- NIH simplified review framework (opens in a new tab)
- NOT-OD-26-018: Common Forms for Biographical Sketch and Current and Pending (Other) Support (opens in a new tab)
- NOT-OD-26-099: NIH Unified Funding Strategy webinar (opens in a new tab)
- NOT-OD-25-068: NIH indirect cost Supplemental Guidance (opens in a new tab)
- Georgetown Law litigation tracker, Massachusetts v. NIH (First Circuit No. 25-1343) (opens in a new tab)
- NIH RePORTER API (opens in a new tab)
- USAspending.gov award search (opens in a new tab)
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open CCSG P30 record
Check PAR-25-444, September 2026 timing, center type, research base, and budget caps.
Compare training route
Use when the need is course-based cancer research education instead of center support.
Compare R01 route
Use when the project is investigator-led cancer science rather than cancer center infrastructure.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What does PAR-25-444 fund?
It funds P30 Cancer Center Support Grants for NCI-Designated Cancer Centers: scientific leadership, Research Programs, Shared Resources, administration, planning and evaluation, developmental funds, community outreach, training coordination, and centralized clinical trial oversight.
Who's eligible to apply for a new CCSG?
A U.S. institution with an annual cancer-focused NIH funding base of at least $10 million in direct costs (Clinical Cancer Center) or $6 million (Basic Cancer Center), as measured by NIH's RCDC system. Renewals need at least $10 million in peer-reviewed cancer-related funding. Only one application per institution is allowed, and new applications can't propose a consortium or request Comprehensive status.
What budget applies?
New Type 1 applications are capped at $1.2 million (Basic), $1.4 million (Clinical), or $1.5 million (Comprehensive) in direct costs per year. Renewal budgets aren't capped but must reflect actual need. In FY2026, the median NCI P30 award was about $4.0 million in total costs, according to NIH RePORTER data.
When are applications due?
The next due dates are January 25, 2027, May 25, 2027, and September 25, 2027, with more dates through September 25, 2028. Applications are due by 5 p.m. local time, and the NOFO expires September 26, 2028.
Does the 2025 simplified review framework apply to the CCSG?
No. NIH's simplified framework covers most research project grants. PAR-25-444 keeps the five separately scored criteria (Significance, Investigators, Innovation, Approach, Environment) plus additional criteria built on the Six Essential Characteristics of a cancer center.
Is the 15% indirect cost cap in effect for CCSG awards?
No. NIH's February 2025 notice setting a 15% indirect rate was blocked in federal court, and the First Circuit ruled against the cap on January 5, 2026. Awards continue to use negotiated F&A rates; check your notice of award terms.
Who should skip this route?
Skip it if the institution can't document the RCDC funding base, Research Programs with at least seven R01-equivalent cancer projects from five PIs each, used Shared Resources, and a center director with real authority.
Last updated October 18, 2026. Corrected October 18, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
RFA-ES-25-002 EHS Core Centers P30 eligibility Guide
EHS Core Centers P30 guide: 7 checks for eligibility, source status, budget, evidence, route fit, review criteria, and team readiness in 2026.
Grants for Cancer Support Organizations 2026: Top Funders
Grants for cancer support organizations in 2026: 1,168 foundations gave to cancer support groups in 990-PF filings, 204 of them in California.
Animal Biological Material Resource Centers P40 Guide
Animal and Biological Material guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
PAR-25-106 Cancer Nanotechnology R01 Eligibility Guide
NIH PAR-25-106 guide: NCI cancer nanotechnology R01 eligibility, clinical-trial-not-allowed fit, nanoscale criteria, and review checks.
PAR-25-153 NCI Assay Screening R01 Eligibility Guide
NIH PAR-25-153 guide: NCI assay-development and screening R01 eligibility, clinical-trial-not-allowed fit, stages, and review checks.
PAR-25-135 NCI K99 eligibility Guide
PAR 25 135 NCI K99 guide: 7 checks for eligibility, deadlines, budget, evidence, route fit, review criteria, and the 2027 K award changes.